Enanta Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Enanta Pharmaceuticals

21/11/2022 22:01

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.27​​ per share for the quarter ended in
September. The mean expectation of eight analysts for the
quarter was for a loss of $1.35 per share.
    * Revenue fell 13.8% to $20.32 million from a year ago;
analysts
expected $22.86 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.27​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Enanta Pharmaceuticals Inc shares had fallen by 9.7% this
quarter and lost 37.4% so far this year.
    * The company reported a quarterly loss of $26.35 million.
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $70.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
21 at 10:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.35          -1.27          Beat
 Jun. 30 2022      -1.39          -1.53          Missed
 Mar. 31 2022      -1.43          -1.63          Missed
 Dec. 31 2021      -1.08          -1.48          Missed